This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Seoul National University. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Ji-Yeon Yun: Innovator in Angiogenic Stem Cell Research
Introduction
Ji-Yeon Yun is a prominent inventor based in Goyang-si, South Korea. He has made significant contributions to the field of regenerative medicine, particularly in the area of stem cell research. His innovative work focuses on enhancing the properties of peripheral blood stem cells to promote angiogenesis, which is crucial for tissue regeneration.
Latest Patents
Ji-Yeon Yun holds a patent for "Peripheral blood stem cells with improved angiogenic properties and use thereof." This patent describes a method for producing peripheral blood stem cells with enhanced angiogenic properties through EPO or APS priming. The cells produced using this method are capable of inducing angiogenesis, making them effective for the regeneration of various tissues affected by ischemic diseases. These diseases include conditions such as myocardial infarction, stroke, and peripheral vascular obstruction, among others.
Career Highlights
Ji-Yeon Yun is affiliated with Seoul National University, where he conducts his research and development activities. His work has garnered attention for its potential applications in treating a range of ischemic conditions, thereby improving patient outcomes and advancing the field of regenerative medicine.
Collaborations
Ji-Yeon Yun collaborates with notable colleagues, including Young-Bae Park and Hyo-Soo Kim. These collaborations enhance the research efforts and contribute to the innovative advancements in stem cell technology.
Conclusion
Ji-Yeon Yun's contributions to the field of stem cell research and angiogenesis represent a significant advancement in regenerative medicine. His innovative methods and collaborative efforts continue to pave the way for new treatments for ischemic diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
